Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

April 1-2, 2016

New York, New York

Continuing Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) - US Physicians
Successful completion of this CME activity enables a participant to earn up to 14.5 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend

This live educational activities are designed to meet the educational needs of hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies and benign hematologic disorders.


Upon successful completion of these educational activities, participants should be able to:

  • Interpret pertinent clinical trial data for standard of care and novel management strategies and assess how their integration into clinical practice has the potential to enhance outcomes in patients with hematologic malignancies and benign hematologic disorders
  • Assess how molecular and genetic abnormalities can be utilized in diagnosis, prognosis, risk stratification and therapy selection for patients with hematologic malignancies and benign hematologic disorders
  • Evaluate the role of stem cell transplant in the era of novel therapies
  • Evaluate the mechanism of action of standard of care and novel therapeutic agents, and define patient populations who would gain the most clinical benefit from their utilization
  • Formulate evidence-based strategies for the management of hematologic malignancies and benign hematologic disorders that take into consideration patient risk factors, disease stage and prior therapeutic regimens